ArticleActa neurologica Belgica2026
Diagnostic accuracy of CSF and plasma pTau-181, pTau-217, and pTau-231 for Alzheimer's disease: a diagnostic meta-analysis.
Article in Acta neurologica Belgica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlzheimer's disease (AD) remains the most common cause of dementia worldwide, yet achieving an accurate early diagnosis continues to pose a major challenge. Recent advances highlight phosphorylated tau (pTau) isoforms-pTau-181, pTau-217, and pTau-231-detected in cerebrospinal fluid (CSF) and plasma as promising biomarkers capable of distinguishing AD from non-Alzheimer's dementias and cognitively healthy individuals (HC). This study aimed to comprehensively assess the diagnostic accuracy of these pTau isoforms through a systematic review and diagnostic meta-analysis.
methodsFollowing PRISMA 2020 guidelines and PROSPERO registration (CRD42025632278), we performed a systematic search of PubMed, Scopus, and Web of Science databases through September 2025. Eligible studies evaluated the diagnostic performance of pTau-181, pTau-217, or pTau-231 in CSF or plasma using established AD reference standards. Pooled sensitivity, specificity, diagnostic odds ratio (DOR), and area under the curve (AUC) were calculated using random-effects models. Clinical applicability was assessed via Fagan's nomogram, and publication bias was examined using Deeks' funnel plot asymmetry test.
resultsForty-eight studies encompassing diverse international cohorts met inclusion criteria. In differentiating AD from HC, CSF pTau-217 demonstrated the highest diagnostic precision (sensitivity = 0.95; specificity = 0.91), outperforming pTau-181 and pTau-231 (AUC = 0.90 each). Plasma biomarkers also exhibited strong diagnostic value: plasma pTau-181 achieved sensitivity of 0.88, specificity of 0.81, and AUC of 0.91, while plasma pTau-231 displayed sensitivity of 0.84, specificity of 0.87, and AUC of 0.86, with low interstudy heterogeneity. Comparative analyses confirmed significantly higher pTau concentrations in AD relative to both non-AD dementias and healthy controls. The overall certainty of evidence ranged from moderate to high, supporting the robustness of these findings.
conclusionsThis meta-analysis supports the strong diagnostic performance of pTau isoforms, particularly CSF pTau-217, in distinguishing Alzheimer's disease from healthy controls and non-Alzheimer's dementias. However, evidence for CSF pTau-217 is limited and largely derived from limited number of studies. Although plasma pTau-181 and pTau-231 show promising diagnostic accuracy, further real-world validation, assay standardization, and assessment within established diagnostic pathways are needed. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
42350884What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.